|Novo Nordisk A/S is a healthcare company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition, it is engaged in areas, such as haemophilia, growth hormone therapy and hormone replacement therapy. It manufactures and markets pharmaceutical products and services to patients, the medical profession and society. It operates in two segments: diabetes care and biopharmaceuticals. It operates in four geographical regions North America: the United States and Canada; Europe: the European Union, EFTA, Albania, Bosnia-Herzegovina, Croatia, Macedonia, Serbia, Montenegro and Kosovo; Japan and Korea, and International Operations: all other countries, including China. Its products include Victoza, NovoNorm/Prandin/PrandiMet, NovoSeven and Norditropin.